Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphosys Ag ADR (NQ: MOR )

18.05 -0.08 (-0.44%)
Streaming Delayed Price Updated: 12:37 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 320,653
Open 18.11
Bid (Size) 18.04 (4)
Ask (Size) 18.05 (4)
Prev. Close 18.13
Today's Range 18.03 - 18.11
52wk Range 4.185 - 18.30
Shares Outstanding 32,890,046
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
Via ACCESSWIRE
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow. 
Via Benzinga

Performance

YTD
+87.24%
+87.24%
1 Month
-0.72%
-0.72%
3 Month
+82.88%
+82.88%
6 Month
+137.81%
+137.81%
1 Year
+249.81%
+249.81%

More News

Read More
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
From MorphoSys AG
Via Business Wire
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Via ACCESSWIRE
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
Via ACCESSWIRE
MorphoSys: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For MorphoSys
Via Benzinga
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
Via ACCESSWIRE
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From MorphoSys AG
Via Business Wire
Earnings Scheduled For March 13, 2024
Via Benzinga
Dow Plummets on Rising Bond Yields, MCD Earnings
Via Talk Markets
Topics Stocks
Exposures US Equities
MorphoSys AG (NASDAQ: MOR) Near the Top of Equities by Percentage Gain on 2/5
Via Investor Brand Network
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Via Talk Markets
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Via InvestorPlace
Exit Now! 3 Biotech Stocks to Sell in February 2024
Via InvestorPlace
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
Via Benzinga
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
Via Investor's Business Daily
Why Is MorphoSys (MOR) Stock Up 50% Today?
Via InvestorPlace
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
Via ACCESSWIRE
Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
Via ACCESSWIRE
Philips Reports Q4 Results, Joins Ryanair And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.